Exercise eased functional dyspepsia in a 260-person trial

Functional dyspepsia is persistent upper-abdominal discomfort, fullness and nausea without a structural cause, and it is notoriously hard to treat with drugs alone. Clinicians often tell patients to move more, yet the evidence behind that advice has been thin and largely observational, which cannot separate cause from consequence — people with bad symptoms may simply move less. The authors set out to test the link twice: once using genetics to probe direction of effect, and once in a controlled trial to see whether prescribed exercise actually relieves symptoms.

Two analyses were combined. First, a Mendelian randomisation study used genetic variants linked to physical activity traits from genome-wide association studies to estimate whether being more active relates to developing functional dyspepsia. Second, the team ran a randomised controlled trial in which 260 patients with functional dyspepsia were allocated either to a moderate-intensity exercise intervention or to a control group. The primary endpoint was the adequate relief rate of dyspeptic symptoms, with symptom scores measured as secondary outcomes; 114 participants in the exercise arm and 113 controls completed the study.

In the trial, the exercise group had a significantly higher adequate relief rate than controls, 46.9% versus 30.8% (P = 0.008), and showed greater reductions in symptom scores (all P < 0.05). In the genetic analysis, strenuous sports activity was inversely associated with developing functional dyspepsia (inverse variance weighted OR = 0.92, 95% CI 0.88-0.98, P = 0.0047), and a weaker, suggestive inverse association appeared for other exercises such as swimming, cycling, keep fit and fishing (OR = 0.964, 95% CI 0.937-0.993, P = 0.013). The authors note those other exercises were previously classed as moderate intensity.

This adds a randomised layer to a question that had mostly rested on cross-sectional observation, and the two approaches point the same way, which is reassuring. Genetic instruments help address reverse causation, but the odds ratios reported here are close to 1, so the population-level effect on risk looks modest. The trial's endpoint was patient-reported relief, which is meaningful to sufferers but vulnerable to expectation effects when participants know their allocation. Open questions include how long relief lasts, which exercise doses and formats matter, and whether the benefit holds outside this single-country setting.

For someone living with unexplained upper-gut symptoms, this is a reason to think regular moderate activity may be more than a generic wellbeing suggestion — it was linked here to a meaningfully higher chance of adequate symptom relief. It is not evidence that exercise replaces medical assessment, and roughly a third of the control group improved anyway, so symptoms fluctuate on their own. The findings are informational: they describe what happened in one trial and one genetic analysis, not a prescription. Anyone with persistent digestive symptoms still needs proper diagnosis first.